ALK and non-small cell lung carcinoma: In addition, another single-institution phase II study (NCT03256136) is evaluating Nivolumab plus chemotherapy, or Nivolumab in combination with Ipilimumab in EGFR or ALK mutated NSCLC patients who failed TKI therapy.